水解—A/O—MBR工艺处理生物医药综合废水

Hydrolysis Acidification-A/O-MBR Process for Treatment of Biopharmaceutical Wastewater

采用水解酸化—A/O—MBR工艺处理生物医药综合废水,处理规模为360 m3/d。工程运行结果表明,该工艺处理效率高,出水水质稳定,最终出水COD、BOD5、SS、氨氮、总磷分别低于50、10、5、10、0.5 mg/L,粪大肠菌群数<3 MPN/L,同时满足《生物工程类制药工业水污染物排放标准》(GB 21907—2008)表2规定的浓度限值及《城市污水再生利用城市杂用水水质》(GB/T18920—2002)要求,可直接回用。

The combined process of hydrolysis acidification, A/O and MBR was used to treat bio- pharmaceutical wastewater. The treatment capacity was 360 m3/d. The actual operation results showed that the combined process had a high treatment efficiency and a stable effluent quality. The final effluent COD, BODs, SS, ammonia nitrogen, TP and fecal coliform colony were less than 50 rag/L, 10 rag/L, 5 rag/L, 10 rag/L, 0.5 mg/L and 3 MPN/L respectively, meeting the limit values in table 2 in Discharge Standards of Water Pollutants for Pharmaceutical Industry--Bio-pharmaceutical Category （GB 21907 - 2008） and the requirements in the Reuse of Urban Recycling Water--Water Quality Standard for Urban Miscellaneous Water Consumption （GB/T 18920 -2002）. The effluent could be directly reused.